| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
|
2
|
International staging system for multiple myeloma.
|
J Clin Oncol
|
2005
|
11.29
|
|
3
|
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
|
N Engl J Med
|
2003
|
10.67
|
|
4
|
The molecular classification of multiple myeloma.
|
Blood
|
2006
|
8.77
|
|
5
|
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
|
Blood
|
2006
|
7.63
|
|
6
|
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.
|
Cancer Cell
|
2007
|
7.10
|
|
7
|
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.
|
Nat Biotechnol
|
2010
|
7.08
|
|
8
|
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
|
Blood
|
2002
|
5.47
|
|
9
|
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
|
Cancer Cell
|
2006
|
5.01
|
|
10
|
Genetics and cytogenetics of multiple myeloma: a workshop report.
|
Cancer Res
|
2004
|
4.54
|
|
11
|
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.
|
Blood
|
2005
|
4.04
|
|
12
|
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
|
Blood
|
2006
|
3.64
|
|
13
|
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
|
J Clin Oncol
|
2006
|
3.60
|
|
14
|
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
|
Blood
|
2010
|
3.41
|
|
15
|
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
|
Blood
|
2006
|
3.17
|
|
16
|
Multiple myeloma: clinical review and diagnostic imaging.
|
Radiology
|
2004
|
3.12
|
|
17
|
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
|
Blood
|
2009
|
3.02
|
|
18
|
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
|
Blood
|
2007
|
2.91
|
|
19
|
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
|
Blood
|
2006
|
2.91
|
|
20
|
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
|
Br J Haematol
|
2008
|
2.64
|
|
21
|
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
|
J Clin Oncol
|
2010
|
2.58
|
|
22
|
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.
|
Blood
|
2008
|
2.41
|
|
23
|
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
|
Haematologica
|
2006
|
2.40
|
|
24
|
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.
|
Clin Infect Dis
|
2008
|
2.26
|
|
25
|
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
|
Clin Cancer Res
|
2008
|
2.13
|
|
26
|
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
|
J Clin Oncol
|
2007
|
2.13
|
|
27
|
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
|
Haematologica
|
2006
|
2.11
|
|
28
|
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies.
|
Clin Infect Dis
|
2010
|
2.10
|
|
29
|
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
|
Blood
|
2013
|
1.98
|
|
30
|
Cancer and the microenvironment: myeloma-osteoclast interactions as a model.
|
Cancer Res
|
2004
|
1.98
|
|
31
|
Familial myeloma.
|
N Engl J Med
|
2008
|
1.96
|
|
32
|
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
1.95
|
|
33
|
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
|
Blood
|
2012
|
1.93
|
|
34
|
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.
|
Blood
|
2008
|
1.93
|
|
35
|
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia.
|
Arch Pathol Lab Med
|
2004
|
1.85
|
|
36
|
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
|
Blood
|
2010
|
1.84
|
|
37
|
Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.
|
Clin Adv Hematol Oncol
|
2010
|
1.84
|
|
38
|
International prognostic scoring system for Waldenstrom macroglobulinemia.
|
Blood
|
2009
|
1.81
|
|
39
|
High heparanase activity in multiple myeloma is associated with elevated microvessel density.
|
Cancer Res
|
2003
|
1.81
|
|
40
|
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.
|
Proc Natl Acad Sci U S A
|
2010
|
1.78
|
|
41
|
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
|
Br J Haematol
|
2002
|
1.74
|
|
42
|
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
|
Haematologica
|
2010
|
1.73
|
|
43
|
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
|
J Exp Med
|
2007
|
1.73
|
|
44
|
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.
|
Clin Infect Dis
|
2011
|
1.70
|
|
45
|
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
|
Blood
|
2008
|
1.68
|
|
46
|
Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.
|
Blood
|
2002
|
1.67
|
|
47
|
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.
|
Blood
|
2003
|
1.65
|
|
48
|
A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
|
Blood
|
2002
|
1.65
|
|
49
|
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
|
Blood
|
2011
|
1.61
|
|
50
|
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
|
Blood
|
2014
|
1.59
|
|
51
|
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
|
Cancer Cell
|
2006
|
1.58
|
|
52
|
Clinical and biological features of multiple myeloma involving the gastrointestinal system.
|
Haematologica
|
2006
|
1.58
|
|
53
|
Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma.
|
Am J Clin Pathol
|
2012
|
1.57
|
|
54
|
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.
|
Blood
|
2009
|
1.56
|
|
55
|
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
|
Br J Haematol
|
2005
|
1.56
|
|
56
|
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
|
Blood
|
2010
|
1.55
|
|
57
|
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
|
Blood
|
2007
|
1.55
|
|
58
|
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
|
J Clin Oncol
|
2002
|
1.54
|
|
59
|
Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
|
Br J Haematol
|
2002
|
1.54
|
|
60
|
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
|
Haematologica
|
2012
|
1.53
|
|
61
|
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.
|
Clin Cancer Res
|
2007
|
1.53
|
|
62
|
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
|
Br J Haematol
|
2009
|
1.51
|
|
63
|
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
|
Blood
|
2009
|
1.51
|
|
64
|
Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
|
Bone
|
2007
|
1.50
|
|
65
|
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
|
Cytotherapy
|
2010
|
1.50
|
|
66
|
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
|
Cancer
|
2005
|
1.50
|
|
67
|
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
|
Blood
|
2007
|
1.49
|
|
68
|
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
|
Br J Haematol
|
2006
|
1.44
|
|
69
|
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
|
Br J Haematol
|
2008
|
1.44
|
|
70
|
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.
|
Blood
|
2002
|
1.44
|
|
71
|
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms.
|
Blood
|
2007
|
1.42
|
|
72
|
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
|
Blood
|
2008
|
1.41
|
|
73
|
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
|
Mol Cancer Ther
|
2009
|
1.40
|
|
74
|
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival.
|
BMC Med
|
2008
|
1.40
|
|
75
|
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
|
Cancer
|
2005
|
1.36
|
|
76
|
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
|
Blood
|
2007
|
1.33
|
|
77
|
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
|
Semin Oncol
|
2003
|
1.33
|
|
78
|
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
|
Blood
|
2006
|
1.31
|
|
79
|
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer.
|
Cancer
|
2007
|
1.29
|
|
80
|
IMWG consensus on maintenance therapy in multiple myeloma.
|
Blood
|
2012
|
1.29
|
|
81
|
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
|
Br J Haematol
|
2007
|
1.28
|
|
82
|
Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications.
|
Cancer
|
2007
|
1.27
|
|
83
|
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.
|
Br J Haematol
|
2002
|
1.26
|
|
84
|
Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.
|
Blood
|
2009
|
1.25
|
|
85
|
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.
|
Blood
|
2002
|
1.23
|
|
86
|
Survival and years of life lost in different age cohorts of patients with multiple myeloma.
|
J Clin Oncol
|
2010
|
1.20
|
|
87
|
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
|
Blood
|
2002
|
1.20
|
|
88
|
Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling.
|
Immunol Rev
|
2003
|
1.18
|
|
89
|
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
|
Br J Haematol
|
2008
|
1.18
|
|
90
|
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
|
Blood
|
2009
|
1.18
|
|
91
|
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
|
Br J Haematol
|
2003
|
1.18
|
|
92
|
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
|
Blood
|
2009
|
1.16
|
|
93
|
Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q.
|
Genes Chromosomes Cancer
|
2005
|
1.16
|
|
94
|
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.
|
Am J Med
|
2002
|
1.15
|
|
95
|
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.
|
Blood
|
2007
|
1.15
|
|
96
|
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
|
Br J Haematol
|
2004
|
1.14
|
|
97
|
A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
|
Br J Haematol
|
2003
|
1.13
|
|
98
|
Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.
|
Br J Haematol
|
2004
|
1.13
|
|
99
|
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma.
|
Clin Cancer Res
|
2008
|
1.13
|
|
100
|
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
|
Blood
|
2009
|
1.13
|
|
101
|
Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
|
J Clin Oncol
|
2004
|
1.13
|
|
102
|
Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
|
Genes Chromosomes Cancer
|
2008
|
1.12
|
|
103
|
Cure models as a useful statistical tool for analyzing survival.
|
Clin Cancer Res
|
2012
|
1.10
|
|
104
|
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
|
Haematologica
|
2012
|
1.09
|
|
105
|
Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
|
J Clin Oncol
|
2009
|
1.09
|
|
106
|
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.
|
Blood
|
2009
|
1.08
|
|
107
|
Prediction of cytogenetic abnormalities with gene expression profiles.
|
Blood
|
2012
|
1.08
|
|
108
|
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival.
|
Blood
|
2003
|
1.08
|
|
109
|
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.
|
Stem Cells
|
2011
|
1.07
|
|
110
|
RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.
|
Blood
|
2004
|
1.07
|
|
111
|
Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
|
Br J Haematol
|
2003
|
1.06
|
|
112
|
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.
|
J Clin Oncol
|
2003
|
1.06
|
|
113
|
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.
|
Br J Haematol
|
2009
|
1.05
|
|
114
|
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
|
Haematologica
|
2012
|
1.05
|
|
115
|
Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.
|
Br J Haematol
|
2002
|
1.05
|
|
116
|
Multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2002
|
1.05
|
|
117
|
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
|
Cancer
|
2006
|
1.05
|
|
118
|
ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma.
|
Oncogene
|
2005
|
1.04
|
|
119
|
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.
|
Blood
|
2002
|
1.03
|
|
120
|
Optimizing dendritic cell-based immunotherapy in multiple myeloma.
|
Br J Haematol
|
2002
|
1.03
|
|
121
|
Morphologic heterogeneity of renal light-chain deposition disease.
|
Ultrastruct Pathol
|
2008
|
1.03
|
|
122
|
MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
|
Br J Haematol
|
2003
|
1.03
|
|
123
|
Hyperammonemia and encephalopathy in patients with multiple myeloma.
|
Am J Hematol
|
2007
|
1.03
|
|
124
|
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.
|
Br J Haematol
|
2006
|
1.02
|
|
125
|
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.
|
Blood
|
2003
|
1.02
|
|
126
|
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
|
Exp Hematol
|
2003
|
1.02
|
|
127
|
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
|
Blood
|
2011
|
1.02
|
|
128
|
Antimyeloma efficacy of thalidomide in the SCID-hu model.
|
Blood
|
2002
|
1.01
|
|
129
|
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
|
Blood
|
2009
|
1.01
|
|
130
|
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
|
J Immunother
|
2015
|
1.01
|
|
131
|
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
|
Blood
|
2013
|
1.00
|
|
132
|
The blood coagulation mechanism in multiple myeloma.
|
Semin Thromb Hemost
|
2003
|
1.00
|
|
133
|
Cardiac nonamyloidotic immunoglobulin deposition disease.
|
Mod Pathol
|
2006
|
1.00
|
|
134
|
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
|
Blood
|
2013
|
0.99
|
|
135
|
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
0.99
|
|
136
|
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
|
Cancer Res
|
2005
|
0.99
|
|
137
|
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
|
Br J Haematol
|
2006
|
0.99
|
|
138
|
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
|
Blood
|
2004
|
0.99
|
|
139
|
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
|
Clin Lymphoma
|
2003
|
0.99
|
|
140
|
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
|
Cancer
|
2010
|
0.97
|
|
141
|
Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients.
|
Blood
|
2003
|
0.97
|
|
142
|
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
|
Br J Haematol
|
2008
|
0.96
|
|
143
|
Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma.
|
Oncol Nurs Forum
|
2008
|
0.95
|
|
144
|
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
|
Am J Hematol
|
2013
|
0.95
|
|
145
|
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
|
Br J Haematol
|
2010
|
0.95
|
|
146
|
Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
|
J Clin Oncol
|
2005
|
0.95
|
|
147
|
Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications.
|
Cancer
|
2010
|
0.95
|
|
148
|
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.
|
Eur J Haematol
|
2009
|
0.94
|
|
149
|
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
|
Semin Oncol
|
2003
|
0.94
|
|
150
|
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
|
Blood Coagul Fibrinolysis
|
2007
|
0.94
|
|
151
|
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
|
Blood
|
2008
|
0.94
|
|
152
|
Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report.
|
J Clin Oncol
|
2004
|
0.93
|
|
153
|
RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.
|
Blood
|
2009
|
0.92
|
|
154
|
CGO: utilizing and integrating gene expression microarray data in clinical research and data management.
|
Bioinformatics
|
2002
|
0.92
|
|
155
|
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
|
Clin Cancer Res
|
2012
|
0.91
|
|
156
|
Retracted
Duration of survival in patients with myeloma treated with thalidomide.
|
N Engl J Med
|
2008
|
0.90
|
|
157
|
First thalidomide clinical trial in multiple myeloma: a decade.
|
Blood
|
2008
|
0.90
|
|
158
|
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
|
J Immunother
|
2007
|
0.90
|
|
159
|
High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
|
Cancer
|
2008
|
0.90
|
|
160
|
Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma.
|
Stat Appl Genet Mol Biol
|
2004
|
0.89
|
|
161
|
Advances in biology and therapy of multiple myeloma.
|
Hematology Am Soc Hematol Educ Program
|
2003
|
0.89
|
|
162
|
Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.
|
PLoS One
|
2010
|
0.89
|
|
163
|
Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography.
|
Nucl Med Commun
|
2004
|
0.88
|
|
164
|
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
|
Haematologica
|
2013
|
0.87
|
|
165
|
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
|
Int J Hematol
|
2011
|
0.86
|
|
166
|
Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma.
|
Cancer Nurs
|
2011
|
0.86
|
|
167
|
In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.
|
Genes Chromosomes Cancer
|
2014
|
0.86
|
|
168
|
Proteasome inhibitors and bone disease.
|
Semin Hematol
|
2012
|
0.86
|
|
169
|
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.
|
PLoS One
|
2013
|
0.86
|
|
170
|
Using genomics to identify high-risk myeloma after autologous stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
0.85
|
|
171
|
Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma.
|
Blood
|
2007
|
0.85
|
|
172
|
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management.
|
Blood
|
2003
|
0.85
|
|
173
|
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.
|
Br J Haematol
|
2002
|
0.85
|
|
174
|
Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma.
|
Am J Clin Pathol
|
2010
|
0.85
|
|
175
|
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon.
|
Br J Haematol
|
2009
|
0.84
|
|
176
|
ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning.
|
Transfusion
|
2002
|
0.84
|
|
177
|
Bradycardia during therapy for multiple myeloma with thalidomide.
|
Am J Cardiol
|
2004
|
0.84
|
|
178
|
Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer.
|
J Clin Oncol
|
2004
|
0.84
|
|
179
|
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols.
|
Br J Haematol
|
2008
|
0.84
|
|
180
|
Successful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literature.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.83
|
|
181
|
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
|
Br J Haematol
|
2009
|
0.83
|
|
182
|
Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.83
|
|
183
|
Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma.
|
Int J Hematol
|
2002
|
0.82
|
|
184
|
Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.
|
Clin Cancer Res
|
2012
|
0.82
|
|
185
|
Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.82
|
|
186
|
Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
|
Cancer
|
2011
|
0.81
|
|
187
|
Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.
|
BMC Med Genomics
|
2014
|
0.81
|
|
188
|
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
|
PLoS One
|
2013
|
0.81
|
|
189
|
Beta(2)-microglobulin as a negative growth regulator of myeloma cells.
|
Br J Haematol
|
2002
|
0.80
|
|
190
|
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
|
Br J Haematol
|
2009
|
0.80
|
|
191
|
Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.
|
Stat Med
|
2008
|
0.80
|
|
192
|
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
|
Haematologica
|
2008
|
0.79
|
|
193
|
Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.
|
Haematologica
|
2013
|
0.79
|
|
194
|
Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration.
|
Cytotherapy
|
2010
|
0.79
|
|
195
|
Treatment advances in multiple myeloma.
|
Br J Haematol
|
2004
|
0.79
|
|
196
|
Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.
|
Oncotarget
|
2014
|
0.78
|
|
197
|
A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL).
|
Amyloid
|
2002
|
0.78
|
|
198
|
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.
|
Mol Cancer Ther
|
2008
|
0.78
|
|
199
|
Initial report of a family registry of multiple myeloma.
|
Cancer Nurs
|
2009
|
0.77
|
|
200
|
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
|
Br J Haematol
|
2013
|
0.77
|
|
201
|
Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables.
|
J Clin Apher
|
2013
|
0.77
|
|
202
|
Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.
|
Semin Hematol
|
2003
|
0.77
|
|
203
|
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
|
Exp Hematol
|
2013
|
0.77
|
|
204
|
Metronomic chemoimmunotherapy in a patient with refractory Waldenstrom's macroglobulinemia.
|
Leuk Lymphoma
|
2005
|
0.77
|
|
205
|
Infection--an underappreciated cause of bone pain in multiple myeloma.
|
Br J Haematol
|
2003
|
0.76
|
|
206
|
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
|
Invest New Drugs
|
2002
|
0.76
|
|
207
|
Allografting or autografting for myeloma.
|
N Engl J Med
|
2007
|
0.75
|
|
208
|
Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).
|
J Clin Oncol
|
2009
|
0.75
|
|
209
|
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
|
Cancer Med
|
2014
|
0.75
|
|
210
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
211
|
Prognostic implications of cumulative dosing in total therapy 3.
|
Blood
|
2012
|
0.75
|
|
212
|
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
|
J Natl Cancer Inst
|
2009
|
0.75
|
|
213
|
The surgical management of abdominal pain in the multiple myeloma patient.
|
Am J Surg
|
2011
|
0.75
|
|
214
|
Highlights from the 46 th annual meeting of the American Society of Hematology.
|
Clin Adv Hematol Oncol
|
2005
|
0.75
|
|
215
|
Retraction: Barlogie et al. Duration of survival in patients with myeloma treated with thalidomide. N Engl J Med 2008;359:210-2.
|
N Engl J Med
|
2008
|
0.75
|
|
216
|
Morphologic manifestations of combined light-chain deposition disease and light-chain cast nephropathy.
|
Ultrastruct Pathol
|
2007
|
0.75
|
|
217
|
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
|
Leuk Lymphoma
|
2002
|
0.75
|
|
218
|
Gene expression profiling defines a high-risk entity of multiple myeloma.
|
Zhong Nan Da Xue Xue Bao Yi Xue Ban
|
2007
|
0.75
|
|
219
|
A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis.
|
Amyloid
|
2014
|
0.75
|
|
220
|
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
|
Br J Haematol
|
2003
|
0.75
|